Massachusetts 2023-2024 Regular Session

Massachusetts House Bill H3557 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	1 of 1
2	2	HOUSE DOCKET, NO. 1650 FILED ON: 1/18/2023
3	3	HOUSE . . . . . . . . . . . . . . . No. 3557
4	4	The Commonwealth of Massachusetts
5	5	_________________
6	6	PRESENTED BY:
7	7	Michael J. Soter
8	8	_________________
9	9	To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
10	10	Court assembled:
11	11	The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
12	12	An Act relative to cannabis research funding.
13	13	_______________
14	14	PETITION OF:
15	15	NAME:DISTRICT/ADDRESS :DATE ADDED:Michael J. Soter8th Worcester1/18/2023F. Jay Barrows1st Bristol3/27/2023 1 of 2
16	16	HOUSE DOCKET, NO. 1650 FILED ON: 1/18/2023
17	17	HOUSE . . . . . . . . . . . . . . . No. 3557
18	18	By Representative Soter of Bellingham, a petition (accompanied by bill, House, No. 3557) of
19	19	Michael J. Soter and F. Jay Barrows relative to medical cannabis research funding. Cannabis
20	20	Policy.
21	21	The Commonwealth of Massachusetts
22	22	_______________
23	23	In the One Hundred and Ninety-Third General Court
24	24	(2023-2024)
25	25	_______________
26	26	An Act relative to cannabis research funding.
27	27	Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
28	28	of the same, as follows:
29	29	1 Chapter 10 of the General Laws is hereby amended by inserting after section 35SSS the
30	30	2following section:-
31	31	3 Section 35TTT. (a) There shall be a Massachusetts Medical Marijuana Research Fund to
32	32	4research the applications of medical marijuana in commonwealth as it relates to treatment for
33	33	5conditions including cancer, amyotrophic lateral sclerosis, Parkinson’s disease, Alzheimer’s
34	34	6disease, HIV/AIDS, epilepsy, seizures, glaucoma and multiple sclerosis, and any other medical
35	35	7conditions identified by the research director of the cannabis control commission. Expenditures
36	36	8from the fund shall be made by the cannabis control commission, without further appropriation
37	37	9and consistent with the terms of settlements made in connection with claims arising from the
38	38	10manufacture, marketing, distribution or dispensing of opioids, as applicable. The research
39	39	11director at the cannabis control commission shall administer the fund, in consultation with the
40	40	12commissioners of the cannabis control commission. 2 of 2
41	41	13 (b) There shall be credited to the fund: (i) $10,000,000 from the Opioid Recovery and
42	42	14Remediation Fund, established in section 35OOO of chapter 10; (ii) transfers from other funds
43	43	15authorized by the general court and so designated; (iii) funds from public or private sources,
44	44	16including, but not limited to, gifts, grants, donations, rebates and settlements received by the
45	45	17commonwealth designated to the fund; and (iv) any interest earned on such amounts. Amounts
46	46	18credited to the fund shall not be subject to further appropriation and monies remaining in the
47	47	19fund at the end of a fiscal year shall not revert to the General Fund.
48	48	20 (c) Biannually, not later than December 31, the research director of the cannabis control
49	49	21commission shall submit a report with the clerks of the house of representatives and the senate.